PURPOSE: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. PROCEDURES: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV(peak)), average SUV (SUV(ave)), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. RESULTS: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. CONCLUSIONS: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.
PURPOSE: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. PROCEDURES: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV(peak)), average SUV (SUV(ave)), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. RESULTS: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. CONCLUSIONS: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.
Authors: Joerg Theisen; Bernd Krause; Christian Peschel; Roland Schmid; Hans Geinitz; Helmut Friess Journal: World J Gastrointest Surg Date: 2009-11-30
Authors: Eugene Y Chang; Xin Li; Michael Jerosch-Herold; Ryan A Priest; C Kristian Enestvedt; Jingang Xu; Charles S Springer; Blair A Jobe Journal: J Gastrointest Surg Date: 2007-09-01 Impact factor: 3.452
Authors: Ho Seong Kim; Joon Young Choi; Dong Wook Choi; Ho Yeong Lim; Joo Hee Lee; Sun Pyo Hong; Young Seok Cho; Kyung-Han Lee; Byung-Tae Kim Journal: Nucl Med Mol Imaging Date: 2014-02-07